Nutanix Tops Q4 Guidance with 16% ARR Growth, but Valuation Remains Rich

What happened

Nutanix reported fourth-quarter and fiscal 2026 results that exceeded its own guidance, with annual recurring revenue (ARR) growing 16% year over year and free cash flow described as strong. This performance builds on the company's prior momentum: FY2025 had revenue growth of 18%, ARR up 17%, and first full-year GAAP profitability, as detailed in the prior DeepValue report. However, the 16% ARR growth for FY2026 marks a slight deceleration from the prior year's 17%, suggesting that growth may be normalizing even as the company continues to win VMware displacements and expand its hybrid cloud platform. The press release highlights outperformance across all fourth-quarter guided metrics, which is a positive sign of execution, but investors should scrutinize the quality of that beat—whether it stems from sustainable operational improvements or one-time items. Notably, the company's valuation remains stretched: based on the prior report's DCF anchor of ~$35 per share, even after a 26% decline over the past year, the stock likely still trades above intrinsic value unless the market has repriced significantly on these results.

Implication

The better-than-expected Q4 and full-year results suggest that Nutanix continues to execute well and maintain its competitive position in hybrid multicloud and VMware displacement. However, ARR growth slowing from 17% to 16% may indicate the easy gains from the Broadcom/VMware disruption are being lapped, and future growth could further moderate. The company's free cash flow remains strong, which is a key positive, but the prior report highlighted a lack of margin of safety at the then-current price of ~$47.8 versus a DCF estimate of ~$34.9. Unless the stock has declined materially or the market has applied a lower multiple, the risk/reward may still not favor new long positions; existing holders might consider trimming into strength. Longer term, if Nutanix can sustain mid-teens ARR growth and expand margins while resolving governance concerns, the premium could be justified, but at this stage the prudent stance is to wait for a better entry point or more concrete evidence of durable acceleration.

Thesis delta

The prior report's WAIT judgment was based on a lack of margin of safety given premium multiples. The Q4 FY2026 beat reinforces operational strength but does not eliminate the valuation overhang, as ARR growth actually decelerated year over year. Thus, the thesis remains WAIT, with the caveat that a sharp post-earnings sell-off or evidence of reaccelerated growth could upgrade it to a potential buy.